Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Inhibitors of dihydroorotate dehydrogenase cooperate with molnupiravir and N4-hydroxycytidine to suppress SARS-CoV-2 replication
Kim M. Stegmann, Antje Dickmanns, Natalie Heinen, et al.
iScience (2022) Vol. 25, Iss. 5, pp. 104293-104293
Open Access | Times Cited: 25

Showing 25 citing articles:

Comparative evaluation of authorized drugs for treating Covid‐19 patients
Towhidul Islam, Moynul Hasan, Mohammad Saydur Rahman, et al.
Health Science Reports (2022) Vol. 5, Iss. 4
Open Access | Times Cited: 38
COVID-19 therapeutics
Daniele Focosi, Massimo Franchini, Fabrizio Maggi, et al.
Clinical Microbiology Reviews (2024) Vol. 37, Iss. 2
Closed Access | Times Cited: 10
DHODH inhibitors: What will it take to get them into the clinic as antivirals?
Anna Luganini, Donatella Boschi, Marco L. Lolli, et al.
Antiviral Research (2025) Vol. 236, pp. 106099-106099
Open Access
Synthesis and Characterization of DHODH Inhibitors Based on the Vidofludimus Scaffold with Pronounced Anti‐SARS‐CoV‐2 Activity
Christian Gege, Friedrich Hahn, Christina Wangen, et al.
ChemMedChem (2024) Vol. 19, Iss. 19
Open Access | Times Cited: 4
The SARS‐CoV‐2 Omicron (B.1.1.529) variant and the re‐emergence of COVID‐19 in Europe: An alarm for Bangladesh
Md. Rabiul Islam
Health Science Reports (2022) Vol. 5, Iss. 2
Open Access | Times Cited: 21
N4-hydroxycytidine, the active compound of Molnupiravir, promotes SARS-CoV-2 mutagenesis and escape from a neutralizing nanobody
Arne Zibat, Xiaoxiao Zhang, Antje Dickmanns, et al.
iScience (2023) Vol. 26, Iss. 10, pp. 107786-107786
Open Access | Times Cited: 10
The effect of molnupiravir and nirmatrelvir on SARS-CoV-2 genome diversity in severe models of COVID-19
Rebekah Penrice-Randal, Eleanor G. Bentley, Parul Sharma, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 2
Current understanding of nucleoside analogs inhibiting the SARS-CoV-2 RNA-dependent RNA polymerase
Tiantian Xu, Lu Zhang
Computational and Structural Biotechnology Journal (2023) Vol. 21, pp. 4385-4394
Open Access | Times Cited: 7
The Novel hDHODH Inhibitor MEDS433 Prevents Influenza Virus Replication by Blocking Pyrimidine Biosynthesis
Giulia Sibille, Anna Luganini, Stefano Sainas, et al.
Viruses (2022) Vol. 14, Iss. 10, pp. 2281-2281
Open Access | Times Cited: 10
Mechanisms of antiviral activity of the new hDHODH inhibitor MEDS433 against respiratory syncytial virus replication
Anna Luganini, Giulia Sibille, Marta Pavan, et al.
Antiviral Research (2023) Vol. 219, pp. 105734-105734
Open Access | Times Cited: 5
Evaluation of N4-hydroxycytidine incorporation into nucleic acids of SARS-CoV-2-infected host cells by direct measurement with liquid chromatography-mass spectrometry
Krzysztof Urbanowicz, Mikołaj Opiełka, Kim M. Stegmann, et al.
Nucleosides Nucleotides & Nucleic Acids (2024) Vol. 43, Iss. 8, pp. 813-821
Closed Access | Times Cited: 1
Global Challenges After a Global Challenge: Lessons Learned from the COVID-19 Pandemic
Niloufar Yazdanpanah, Constantine Sedikides, Hans D. Ochs, et al.
Advances in experimental medicine and biology (2024), pp. 1-31
Closed Access | Times Cited: 1
Evidence for SARS-CoV-2 infected Golden Syrian hamsters (Mesocricetus auratus) reducing daily energy expenditure and body core temperature
Björn-Patrick Mohl, Claudia Blaurock, Alexander Riek, et al.
Scientific Reports (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1
High protection and transmission-blocking immunity elicited by single-cycle SARS-CoV-2 vaccine in hamsters
Martin J. Lett, Fabian Otte, David Hauser, et al.
npj Vaccines (2024) Vol. 9, Iss. 1
Open Access | Times Cited: 1
Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4′-fluorouridine
Leon Schrell, Hannah L Fuchs, Antje Dickmanns, et al.
Antiviral Research (2024) Vol. 233, pp. 106046-106046
Open Access | Times Cited: 1
Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
Henrik Berg Rasmussen, Peter Riis Hansen
Viruses (2023) Vol. 15, Iss. 11, pp. 2151-2151
Open Access | Times Cited: 3
The synergy between nucleotide biosynthesis inhibitors and antiviral nucleosides: New opportunities against viral infections?
Leandro S. M. Miranda
Archiv der Pharmazie (2022) Vol. 356, Iss. 1
Closed Access | Times Cited: 5
Orally Bioavailable RORγ/DHODH Dual Host-Targeting Small Molecules with Broad-Spectrum Antiviral Activity
Alexandra Herrmann, Christian Gege, Christina Wangen, et al.
Antiviral Research (2024), pp. 106008-106008
Open Access
Inhibitors of dihydroorotate dehydrogenase synergize with the broad antiviral activity of 4′-fluorouridine
Leon Schrell, Hannah L Fuchs, Antje Dickmanns, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access
Increased Susceptibility of Rousettus aegyptiacus Bats to Respiratory SARS-CoV-2 Challenge Despite Its Distinct Tropism for Gut Epithelia in Bats
Björn-Patrick Mohl, Claudia Blaurock, Angele Breithaupt, et al.
Viruses (2024) Vol. 16, Iss. 11, pp. 1717-1717
Open Access
The Trimeric Artesunate Analog TF27, a Broadly Acting Anti-Infective Model Drug, Exerts Pronounced Anti-SARS-CoV-2 Activity Spanning Variants and Host Cell Types
Friedrich Hahn, Christina Wangen, Sigrun Häge, et al.
Pharmaceutics (2022) Vol. 15, Iss. 1, pp. 115-115
Open Access | Times Cited: 2
Single-cycle SARS-CoV-2 vaccine elicits high protection and sterilizing immunity in hamsters
Thomas Klimkait, Martin J. Lett, Fabian Otte, et al.
Research Square (Research Square) (2023)
Open Access
Molnupiravir Revisited—Critical Assessment of Studies in Animal Models of COVID-19
Henrik Berg Rasmussen, And Peter Riis Hansen
(2023)
Open Access
Modeling Lung Development and Diseases with Lung Organoids
Ling-Ling Zhou, Di Liu, Juan Wei, et al.
(2023)
Closed Access
Effects of the 5′‐Triphosphate Metabolites of Ribavirin, Sofosbuvir, Vidarabine, and Molnupiravir on CTP Synthase Catalysis and Filament Formation: Implications for Repurposing Antiviral Agents against SARS‐CoV‐2
Thomas D. Gillis, Stephen L. Bearne
ChemMedChem (2022) Vol. 17, Iss. 23
Open Access
Page 1

Scroll to top